BlueConic Announces Strategic Growth Investment from Vista Equity Partners
BlueConic, the market-leading pure-play customer data platform (CDP), today announced a strategic investment from Vista Equity Partners (“Vista”), the leading global investment firm focused exclusively on enterprise software, data and technology-enabled businesses. The growth capital will help BlueConic further accelerate its mission to provide business users with access to unified and actionable first-party customer data whenever and wherever they need it to transform customer relationships and drive business growth. BlueConic’s existing investors, including Spring Lake Equity Partners, Sigma Prime Ventures, and Converge Venture Partners, will continue as minority investors in the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005756/en/
CEO and founder of BlueConic, Bart Heilbron (Photo: Business Wire)
BlueConic is built to power the modern organization’s transformation toward data-driven, digital-first customer engagement. Used by over 300 companies worldwide, including Hearst Newspapers, Heineken, ING, T-Mobile, and VF Corporation, it is the only CDP with a flexible, scalable, and privacy-driven architecture designed to help brands and publishers unify and activate customer data as the engine of business growth.
“In today’s privacy-first era, I truly believe that Vista is the best possible partner to help BlueConic – and our customers – fully capitalize on the growing demand for the collection and use of consented first-party data,” said Bart Heilbron, Founder and CEO of BlueConic. “This investment marks an exciting milestone in our company’s journey that will allow us to leverage Vista’s substantial knowledge and expertise as we continue on our mission to transform how companies operate by putting unified, actionable first-party data in the hands of growth-focused users. The partnership is an incredible validation of our vision, team and platform, and we’re thrilled to leverage the experience of the Vista platform going forward.”
The investment in BlueConic was led by Vista’s Endeavor Fund, which is focused on mission-critical, high-growth enterprise software, data, and technology-enabled businesses seeking to expand their impact in the markets they serve. Endeavor partners with companies and their management teams, providing the capital, expertise, and support to build an operational foundation for sustainable growth while accelerating market leadership.
“As companies ramp investments in new digital transformation initiatives to fuel growth, the ability to understand and activate unique first-party data while ensuring the digital experience remains privacy-compliant becomes increasingly important,” said Rachel Arnold, Senior Managing Director and Co-Head of Vista's Endeavor Fund. “BlueConic’s management team envisioned this trend and built a highly-scalable platform that has helped them become the category leader in enabling customers to glean and utilize insights effectively. We are impressed with what the BlueConic team has accomplished so far and look forward to fueling the next phase of growth for the business.”
BlueConic, the leading pure-play customer data platform, liberates companies’ first-party data from disparate systems and makes it accessible wherever and whenever it is required to transform customer relationships and drive business growth. Over 300 companies worldwide, including Hearst Newspapers, Heineken, ING, T-Mobile, UEFA, and VF Corp, use BlueConic to unify data into persistent, individual-level profiles, and then activate it across customer touchpoints and systems in support of a wide range of growth-focused initiatives, including customer lifecycle orchestration, modeling and analytics, digital products and experiences, audience-based monetization, and more. BlueConic is a global company with offices in the US and Europe. Learn more at http://www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.
About Vista Equity Partners
Vista is a leading global investment firm with more than $86 billion in assets under management as of September 30, 2021. The firm exclusively invests in enterprise software, data and technology-enabled organizations across private equity, permanent capital, credit, and public equity strategies, bringing an approach that prioritizes creating enduring market value for the benefit of its global ecosystem of investors, companies, customers, and employees. Vista’s investments are anchored by a sizable long-term capital base, experience in structuring technology-oriented transactions and proven, flexible management techniques that drive sustainable growth. Vista believes the transformative power of technology is the key to an even better future – a healthier planet, a smarter economy, a diverse and inclusive community, and a broader path to prosperity. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on Twitter, @Vista_Equity.
© 2022 BlueConic®, Inc. All Rights Reserved. Any disclosure, copying, or distribution without permission is prohibited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Karolina Throssell, Iden Marketing
email@example.com or +44 7855751005
Vista Equity Partners
firstname.lastname@example.org or 512-730-2400
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station9.12.2022 20:04:00 CET | Press release
RevBio, Inc., announced that anexperiment to study Tetranite®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS). On Saturday, November 26, 2022, the study materials were launched to the space station on SpaceX’s 26th Commercial Resupply Services (SpaceX CRS-26) mission, sponsored by the ISS National Laboratory. This in vivo research, which will be conducted over the next two months on the ISS, will examine the biomaterial’s ability to regenerate bone when used in a microgravity environment where bone growing conditions and the ability to regenerate new bone tissue is significantly compromised. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005635/en/ RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station. This Experiment will Examine TETRANITE’S Ability to Regenerate Bone under the Condition of
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials9.12.2022 14:00:00 CET | Press release
Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 15% of breast cancers are considered triple negative and are associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes.1,2 It is estimated that only 12% of patients with metastatic TNBC survive five years after diagnosis and median overall survival is between 12 to 18 months.1,3 In the TNBC cohort of TROPION-PanTumor01 (n=44)
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases9.12.2022 14:00:00 CET | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda’s latest research focuses on improving long-term outcomes for patients with hematologic diseases. Takeda’s presentations will include oral sessions detailing a three-year update of the Phase 3 OPTIC trial demonstrating the efficacy and safety of ICLUSIG® (ponatinib) in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML), and results from a first-in-human Phase 1/2 study evaluating modakafusp alfa (TAK-573) in patients with relapsed / refractory multiple myeloma. “Our latest research is focused on investigating novel mechanisms of action, as well as optimizing approved treatments to improve long-term outcomes and more deeply understand and address unmet needs for patients across a range of hematologic diseases,” said Awny Farajallah, M.D., Head of Global Med
Tecnotree Advances to Acquire Top AIML Platform - CognitiveScale in North America to further Enhance 5G Use case Penetration9.12.2022 13:23:00 CET | Press release
Tecnotree is a market leader in 5G digital Business Support Systems (BSS), with AI/ML capabilities and multi-cloud extensibility. Tecnotree’s global footprint with over 90 Telecom customers in 70 countries around the world, supports ecosystems of over 1 billion subscribers. Tecnotree is the first Digital Platform Service provider to be Platinum Badge Certified by TM Forum for Real-world Open API standards. The company also provides B2B2X partner ecosystem and fintech services for monetization beyond connectivity across gaming, healthcare, education, and banking. Tecnotree has been recognized by Gartner for revenue management and monetization as well as for customer experience management solutions and enjoys the position of a leading stock on the Helsinki Nasdaq since 2020. CognitiveScale (CS) is United States based pioneer in the space of AI Engineering and provides solutions for scalable enterprise AI development and deployment. CognitiveScale is backed by over 100 granted AI patents
Another Sustainability Award for NTHU9.12.2022 10:00:00 CET | Press release
National Tsing Hua University (NTHU) in Taiwan has been awarded the Taiwan University Sustainability Award for the second year in a row! The Award was announced at the 15th Taiwan Corporate Sustainability Awards (TCSA) recently held by the Taiwan Institute for Sustainable Energy (TAISE). Standing out amongst the 47 participating universities, NTHU was ranked first in the comprehensive evaluation, and in the individual competitions received the University Sustainability Report Gold Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221209005001/en/ NTHU president W. John Kao (right) accepting the Taiwan University Sustainability Award from You Si-kun, president of the Legislative Yuan. (Photo: National Tsing Hua University) The judges cited the exemplary way in which NTHU has adopted an innovative approach to integrating classroom learning, campus activities and social service, thereby enriching students’ education and cre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom